Loading data for CSTL — first visit, this takes a few seconds.

Castle Biosciences, Inc. (CSTL)

NasdaqGM: CSTL · 即時價格 · USD

33.42

-0.02 (-0.06%)

收盤價： Sep 04, 2026, 8:00 PM

32.91

+0.00%

盤後: 7:30 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	22.02
市值	1.01B
營收 (ttm)	357M
淨利（ttm）	-19.4M
	1.00
	-0.64
	n/a
	-33.28
P/B (ttm)	2.14
P/S (ttm)	2.81
財報日期	Nov 2, 2026

賣價	40.14
成交量	200,261
20 日平均成交量	400,687
開盤價	33.36
前收盤價	33.44
當日區間	32.69 - 34.73
52 週範圍	17.72 - 44.28
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 CSTL

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; Tissue...

[閱讀更多]

產業 Diagnostics & Research

類股 Healthcare

IPO 日期 Jul 25, 2019

員工 1,002

證券交易所 NasdaqGM

股票代號 CSTL

網站 https://castlebiosciences.com

完整的公司簡介

財務表現

Castle Biosciences 在 2025 年的營收為 344.23M，較前一年的 332.07M 增加 3.66%。淨利為 -24.16M，較前期減少 -232.41%。

財務報表

財報驚奇

Castle Biosciences 已於 Jul 30, 2026 公布季度財報：

營收為 $103.55M 低於預期 $0, 年增 20.14% 成長.
每股盈餘為 -0.07 超出預期 0.34, 年增 -146.67% 下滑.

下次財報發布

Castle Biosciences, Inc. 的下次財報預計於 Nov 2, 2026, 盤中。
分析師預估營收 ... 升級

價格為何變動

新聞動態

1 週前 · Zacks

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know

Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 週前 · Simply Wall St.

Castle Biosciences (CSTL) Rallies On Earnings Optimism, Is The Stock Still Cheap?

Shares of Castle Biosciences (CSTL) have recently risen about 37%, following increasing agreement among Wall Street analysts on earnings estimate revisions that point to a more constructive view of th...

2 週前 · Zacks

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?

The consensus price target hints at a 31.5% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning...

3 週前 · MarketBeat

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction

Castle Biosciences (NASDAQ:CSTL) reported continued momentum in its core diagnostic franchises during the second quarter, prompting the company to raise its outlook by more than the amount of its repo...

1 月前 · Moby

Castle Biosciences, Inc. Q2 2026 Earnings Call Summary

Moby summary of Castle Biosciences, Inc.'s Q2 2026 earnings call

第 1 頁，共 2 頁

Castle Biosciences, Inc. (CSTL)